F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy

Aleksandra I. Adamovich; Amanda Ewart Toland; Jeffrey D. Parvin

doi:10.1016/j.molcel.2018.12.019

F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy

Aleksandra I. Adamovich
, Amanda Ewart Toland
, Jeffrey D. Parvin

Research output: Contribution to journal › Short survey › peer-review

4 Scopus citations

Abstract

PARP inhibitor (PARPi) therapy targets BRCA1/2 mutant tumor cells, but acquired resistance limits its effectiveness. In this issue of Molecular Cell, Marzio et al. (2019) identify a novel mechanism of resistance to PARPi through regulation of RAD51 protein stability via an SCF ubiquitin ligase dependent on EMI1.

Original language	English
Pages (from-to)	195-196
Number of pages	2
Journal	Molecular Cell
Volume	73
Issue number	2
DOIs	https://doi.org/10.1016/j.molcel.2018.12.019
State	Published - Jan 17 2019

Access to Document

10.1016/j.molcel.2018.12.019

Cite this

@article{2a24c7aa77f3487b9fcb372499ddaa09,

title = "F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy",

abstract = "PARP inhibitor (PARPi) therapy targets BRCA1/2 mutant tumor cells, but acquired resistance limits its effectiveness. In this issue of Molecular Cell, Marzio et al. (2019) identify a novel mechanism of resistance to PARPi through regulation of RAD51 protein stability via an SCF ubiquitin ligase dependent on EMI1.",

author = "Adamovich, \{Aleksandra I.\} and Toland, \{Amanda Ewart\} and Parvin, \{Jeffrey D.\}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = jan,

day = "17",

doi = "10.1016/j.molcel.2018.12.019",

language = "English",

volume = "73",

pages = "195--196",

journal = "Molecular Cell",

issn = "1097-2765",

number = "2",

}

TY - JOUR

T1 - F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy

AU - Adamovich, Aleksandra I.

AU - Toland, Amanda Ewart

AU - Parvin, Jeffrey D.

PY - 2019/1/17

Y1 - 2019/1/17

N2 - PARP inhibitor (PARPi) therapy targets BRCA1/2 mutant tumor cells, but acquired resistance limits its effectiveness. In this issue of Molecular Cell, Marzio et al. (2019) identify a novel mechanism of resistance to PARPi through regulation of RAD51 protein stability via an SCF ubiquitin ligase dependent on EMI1.

AB - PARP inhibitor (PARPi) therapy targets BRCA1/2 mutant tumor cells, but acquired resistance limits its effectiveness. In this issue of Molecular Cell, Marzio et al. (2019) identify a novel mechanism of resistance to PARPi through regulation of RAD51 protein stability via an SCF ubiquitin ligase dependent on EMI1.

UR - https://www.scopus.com/pages/publications/85059349531

U2 - 10.1016/j.molcel.2018.12.019

DO - 10.1016/j.molcel.2018.12.019

M3 - Short survey

C2 - 30658107

AN - SCOPUS:85059349531

SN - 1097-2765

VL - 73

SP - 195

EP - 196

JO - Molecular Cell

JF - Molecular Cell

IS - 2

ER -

F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this